Predict your next investment

Government
cirm.ca.gov

See what CB Insights has to offer

Investments

16

Portfolio Exits

7

Partners & Customers

2

About California Institute of Regenerative Medicine

California Institute of Regenerative Medicine (CIRM) was created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, CIRM actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today's most promising stem cell technologies.

California Institute of Regenerative Medicine Headquarters Location

210 King Street

San Francisco, California, 94107,

United States

415-396-9100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest California Institute of Regenerative Medicine News

HACARUS(ハカルス)、京都大学ウイルス・再生医科学研究所と、がん細胞の代謝の仕組み解明を目指す共同研究を開始

Oct 20, 2021

2010年 University of California San Diego 博士研究員              California Institute of Regenerative Medicine リサーチフェロー 2013年 University of Georgia, Department of Biochemistry & Molecular Biology 助教授 2019年 University of Georgia, Department of Biochemistry & Molecular Biology 准教授 2019年 京都大学ウイルス・再生医科学研究所 教授

California Institute of Regenerative Medicine Investments

16 Investments

California Institute of Regenerative Medicine has made 16 investments. Their latest investment was in BioEclipse Therapeutics as part of their Grant on April 4, 2022.

CBI Logo

California Institute of Regenerative Medicine Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/26/2022

Grant

BioEclipse Therapeutics

$8M

Yes

1

9/24/2021

Grant

The Lundquist Institute for Biomedical Innovation

$5M

Yes

1

5/1/2020

Grant

ExCellThera

$1.5M

Yes

2

12/6/2017

Grant

Subscribe to see more

$99M

Subscribe to see more

10

10/11/2017

Grant - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/26/2022

9/24/2021

5/1/2020

12/6/2017

10/11/2017

Round

Grant

Grant

Grant

Grant

Grant - III

Company

BioEclipse Therapeutics

The Lundquist Institute for Biomedical Innovation

ExCellThera

Subscribe to see more

Subscribe to see more

Amount

$8M

$5M

$1.5M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

2

10

10

California Institute of Regenerative Medicine Portfolio Exits

7 Portfolio Exits

California Institute of Regenerative Medicine has 7 portfolio exits. Their latest portfolio exit was ViaCyte on July 11, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/11/2022

Acquired

$99M

9

2/17/2021

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

9/3/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

10/31/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/28/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/11/2022

2/17/2021

9/3/2019

10/31/2018

6/28/2018

Exit

Acquired

Reverse Merger

Acquired

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

9

10

10

10

10

California Institute of Regenerative Medicine Partners & Customers

2 Partners and customers

California Institute of Regenerative Medicine has 2 strategic partners and customers. California Institute of Regenerative Medicine recently partnered with Quintiles Transnational on June 6, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

6/15/2016

Partner

United States

CIRM Creates First of its Kind Center to Accelerate Stem Cell Development.

`` This partnership with Quintiles Transnational Inc. means that CIRM projects will not only be accelerated , but that CIRM will also realize a reasonable financial return on this investment . ''

2

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

6/15/2016

Type

Partner

Partner

Business Partner

Country

United States

United States

News Snippet

CIRM Creates First of its Kind Center to Accelerate Stem Cell Development.

`` This partnership with Quintiles Transnational Inc. means that CIRM projects will not only be accelerated , but that CIRM will also realize a reasonable financial return on this investment . ''

Subscribe to see more

Subscribe to see more

Sources

2

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.